<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 20:01:54 -0700</creation_date>
  <update_date>2013-01-15 20:01:54 -0700</update_date>
  <accession>HMDBP07718</accession>
  <secondary_accessions>
    <accession>13427</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
    <synonym>AMPA-selective glutamate receptor 2</synonym>
    <synonym>GluA2</synonym>
    <synonym>GluR-2</synonym>
    <synonym>GluR-B</synonym>
    <synonym>GluR-K2</synonym>
    <synonym>Glutamate receptor ionotropic, AMPA 2</synonym>
  </synonyms>
  <gene_name>GRIA2</gene_name>
  <general_function>Involved in ionotropic glutamate receptor activity</general_function>
  <specific_function>Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L- glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inactive state, characterized by the presence of bound agonist</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00464</accession>
      <name>Calcium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00148</accession>
      <name>L-Glutamic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14382</accession>
      <name>Butabarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14386</accession>
      <name>Butalbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14451</accession>
      <name>Talbutal</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14457</accession>
      <name>Pentobarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14562</accession>
      <name>Secobarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14606</accession>
      <name>Metharbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14737</accession>
      <name>Thiopental</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14932</accession>
      <name>Primidone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14987</accession>
      <name>Methylphenobarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15436</accession>
      <name>Quinidine barbiturate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15440</accession>
      <name>Amobarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15441</accession>
      <name>Aprobarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15442</accession>
      <name>Butethal</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15443</accession>
      <name>Heptabarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13940</accession>
      <name>3'-Hydroxyhexobarbital</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>substrate-specific transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ligand-gated ion channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>extracellular ligand-gated ion channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>excitatory extracellular ligand-gated ion channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>extracellular-glutamate-gated ion channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>molecular transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>signal transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transmembrane receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>glutamate receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ionotropic glutamate receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>establishment of localization</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>ion transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Cell membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
    <subcellular_location>Cell junction</subcellular_location>
    <subcellular_location>synapse</subcellular_location>
    <subcellular_location>postsynaptic cell membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:4</chromosome_location>
    <locus>4q32-q33</locus>
    <gene_sequence>&gt;2652 bp
ATGCAAAAGATTATGCATATTTCTGTCCTCCTTTCTCCTGTTTTATGGGGACTGATTTTT
GGTGTCTCTTCTAACAGCATACAGATAGGGGGGCTATTTCCTAGGGGCGCCGATCAAGAA
TACAGTGCATTTCGAGTAGGGATGGTTCAGTTTTCCACTTCGGAGTTCAGACTGACACCC
CACATCGACAATTTGGAGGTGGCAAACAGCTTCGCAGTCACTAATGCTTTCTGCTCCCAG
TTTTCGAGAGGAGTCTATGCTATTTTTGGATTTTATGACAAGAAGTCTGTAAATACCATC
ACATCATTTTGCGGAACACTCCACGTCTCCTTCATCACTCCCAGCTTCCCAACAGATGGC
ACACATCCATTTGTCATTCAGATGAGACCCGACCTCAAAGGAGCTCTCCTTAGCTTAGTT
GAATACTATCAATGGGACAAGTTTGCATACCTCTATGACAGTGACAGAGGCTTATCAACA
CTGCAAGCTGTGCTGGATTCTGCTGCTGAAAAGAAATGGCAAGTGACTGCTATCAATGTG
GGAAACATTAACAATGACAAGAAAGATGAGATGTACCGATCACTTTTTCAAGATCTGGAG
TTAAAAAAGGAACGGCGTGTAATTCTGGACTGTGAAAGGGATAAAGTAAACGACATTGTA
GACCAGGTTATTACCATTGGAAAACATGTTAAAGGGTACCACTACATCATTGCAAATCTG
GGATTTACTGATGGAGACCTATTAAAAATCCAGTTTGGAGGTGCAAATGTCTCTGGATTT
CAGATAGTGGACTATGATGATTCGTTGGTATCTAAATTTATAGAAAGATGGTCAACACTG
GAAGAAAAAGAATACCCTGGAGCTCACACAACAACAATTAAGTATACTTCTGCTCTGACC
TATGATGCCGTTCAAGTGATGACTGAAGCCTTCCGCAACCTAAGGAAGCAAAGAATTGAA
ATCTCCCGAAGGGGGAATGCAGGAGACTGTCTGGCAAACCCAGCAGTGCCCTGGGGACAA
GGTGTAGAAATAGAAAGGGCCCTCAAACAGGTTCAGGTTGAAGGTCTCTCAGGAAATATA
AAGTTTGACCAGAATGGAAAAAGAATAAACTATACAATTAACATCATGGAGCTCAAAACT
AATGGGCCCCGGAAGATTGGCTACTGGAGTGAAGTGGACAAAATGGTTGTTACCCTTACT
GAGCTCCCTTCTGGAAATGACACCTCTGGGCTTGAGAATAAGACTGTTGTTGTCACCACA
ATTTTGGAATCTCCGTATGTTATGATGAAGAAAAATCATGAAATGCTTGAAGGCAATGAG
CGCTATGAGGGCTACTGTGTTGACCTGGCTGCAGAAATCGCCAAACATTGTGGGTTCAAG
TACAAGTTGACAATTGTTGGTGATGGCAAGTATGGGGCCAGGGATGCAGACACGAAAATT
TGGAATGGGATGGTTGGAGAACTTGTATATGGGAAAGCTGATATTGCAATTGCTCCATTA
ACTATTACCCTTGTGAGAGAAGAGGTGATTGACTTCTCAAAGCCCTTCATGAGCCTCGGG
ATATCTATCATGATCAAGAAGCCTCAGAAGTCCAAACCAGGAGTGTTTTCCTTTCTTGAT
CCTTTAGCCTATGAGATCTGGATGTGCATTGTTTTTGCCTACATTGGGGTCAGTGTAGTT
TTATTCCTGGTCAGCAGATTTAGCCCCTACGAGTGGCACACTGAGGAGTTTGAAGATGGA
AGAGAAACACAAAGTAGTGAATCAACTAATGAATTTGGGATTTTTAATAGTCTCTGGTTT
TCCTTGGGTGCCTTTATGCGGCGAGGATGCGATATTTCGCCAAGATCCCTCTCTGGGCGC
ATTGTTGGAGGTGTGTGGTGGTTCTTTACCCTGATCATAATCTCCTCCTACACGGCTAAC
TTAGCTGCCTTCCTGACTGTAGAGAGGATGGTGTCTCCCATCGAAAGTGCTGAGGATCTT
TCTAAGCAAACAGAAATTGCTTATGGAACATTAGACTCTGGCTCCACTAAAGAGTTTTTC
AGGAGATCTAAAATTGCAGTGTTTGATAAAATGTGGACCTACATGCGGAGTGCGGAGCCC
TCTGTGTTTGTGAGGACTACGGCCGAAGGGGTGGCTAGAGTGCGGAAGTCCAAAGGGAAA
TATGCCTACTTGTTGGAGTCCACGATGAACGAGTACATTGAGCAAAGGAAGCCTTGCGAC
ACCATGAAAGTTGGTGGAAACCTGGATTCCAAAGGCTATGGCATCGCAACACCTAAAGGA
TCCTCATTAAGAAATGCGGTTAACCTCGCAGTACTAAAACTGAATGAACAAGGCCTGTTG
GACAAATTGAAAAACAAATGGTGGTACGACAAAGGAGAGTGCGGCAGCGGGGGAGGTGAT
TCCAAGGAAAAGACCAGTGCCCTCAGTCTGAGCAACGTTGCTGGAGTATTCTACATCCTT
GTCGGGGGCCTTGGTTTGGCAATGCTGGTGGCTTTGATTGAGTTCTGTTACAAGTCAAGG
GCCGAGGCGAAACGAATGAAGGTGGCAAAGAATGCACAGAATATTAACCCTTCTTCCTCG
CAGAATTCACAGAATTTTGCAACTTATAAGGAAGGTTACAACGTATATGGCATCGAAAGT
GTTAAAATTTAG</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>883</residue_number>
    <molecular_weight>98820.3</molecular_weight>
    <theoretical_pi>7.66</theoretical_pi>
    <pfams>
      <pfam>
        <name>ANF_receptor</name>
        <pfam_id>PF01094</pfam_id>
      </pfam>
      <pfam>
        <name>Lig_chan</name>
        <pfam_id>PF00060</pfam_id>
      </pfam>
      <pfam>
        <name>Lig_chan-Glu_bd</name>
        <pfam_id>PF10613</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>544-564</region>
      <region>625-645</region>
      <region>813-833</region>
    </transmembrane_regions>
    <signal_regions>
      <region>1-24</region>
    </signal_regions>
    <protein_sequence>&gt;Glutamate receptor 2
MQKIMHISVLLSPVLWGLIFGVSSNSIQIGGLFPRGADQEYSAFRVGMVQFSTSEFRLTP
HIDNLEVANSFAVTNAFCSQFSRGVYAIFGFYDKKSVNTITSFCGTLHVSFITPSFPTDG
THPFVIQMRPDLKGALLSLIEYYQWDKFAYLYDSDRGLSTLQAVLDSAAEKKWQVTAINV
GNINNDKKDEMYRSLFQDLELKKERRVILDCERDKVNDIVDQVITIGKHVKGYHYIIANL
GFTDGDLLKIQFGGANVSGFQIVDYDDSLVSKFIERWSTLEEKEYPGAHTTTIKYTSALT
YDAVQVMTEAFRNLRKQRIEISRRGNAGDCLANPAVPWGQGVEIERALKQVQVEGLSGNI
KFDQNGKRINYTINIMELKTNGPRKIGYWSEVDKMVVTLTELPSGNDTSGLENKTVVVTT
ILESPYVMMKKNHEMLEGNERYEGYCVDLAAEIAKHCGFKYKLTIVGDGKYGARDADTKI
WNGMVGELVYGKADIAIAPLTITLVREEVIDFSKPFMSLGISIMIKKPQKSKPGVFSFLD
PLAYEIWMCIVFAYIGVSVVLFLVSRFSPYEWHTEEFEDGRETQSSESTNEFGIFNSLWF
SLGAFMQQGCDISPRSLSGRIVGGVWWFFTLIIISSYTANLAAFLTVERMVSPIESAEDL
SKQTEIAYGTLDSGSTKEFFRRSKIAVFDKMWTYMRSAEPSVFVRTTAEGVARVRKSKGK
YAYLLESTMNEYIEQRKPCDTMKVGGNLDSKGYGIATPKGSSLRNAVNLAVLKLNEQGLL
DKLKNKWWYDKGECGSGGGDSKEKTSALSLSNVAGVFYILVGGLGLAMLVALIEFCYKSR
AEAKRMKVAKNAQNINPSSSQNSQNFATYKEGYNVYGIESVKI</protein_sequence>
  </protein_properties>
  <genbank_protein_id>14714846</genbank_protein_id>
  <uniprot_id>P42262</uniprot_id>
  <uniprot_name>GRIA2_HUMAN</uniprot_name>
  <pdb_ids>
    <pdb_id>1WVJ</pdb_id>
  </pdb_ids>
  <genbank_gene_id>BC010574</genbank_gene_id>
  <genecard_id>GRIA2</genecard_id>
  <geneatlas_id>GRIA2</geneatlas_id>
  <hgnc_id>HGNC:4572</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Sun W, Ferrer-Montiel AV, Montal M: Primary structure and functional expression of the AMPA/kainate receptor subunit 2 from human brain. Neuroreport. 1994 Jan 12;5(4):441-4.</reference_text>
      <pubmed_id>8003671</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Paschen W, Hedreen JC, Ross CA: RNA editing of the glutamate receptor subunits GluR2 and GluR6 in human brain tissue. J Neurochem. 1994 Nov;63(5):1596-602.</reference_text>
      <pubmed_id>7523595</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kolleker A, Zhu JJ, Schupp BJ, Qin Y, Mack V, Borchardt T, Kohr G, Malinow R, Seeburg PH, Osten P: Glutamatergic plasticity by synaptic delivery of GluR-B(long)-containing AMPA receptors. Neuron. 2003 Dec 18;40(6):1199-212.</reference_text>
      <pubmed_id>14687553</pubmed_id>
    </reference>
    <reference>
      <reference_text>Dev KK, Nakanishi S, Henley JM: The PDZ domain of PICK1 differentially accepts protein kinase C-alpha and GluR2 as interacting ligands. J Biol Chem. 2004 Oct 1;279(40):41393-7. Epub 2004 Jul 9.</reference_text>
      <pubmed_id>15247289</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>L-Glutamic acid</name>
        <accession>HMDB00148</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>L-Glutamic acid</name>
        <accession>HMDB00148</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>L-Glutamic acid</name>
        <accession>HMDB00148</accession>
      </metabolite>
      <reference>
        <reference_text>Henley JM, Jenkins R, Hunt SP: Localisation of glutamate receptor binding sites and mRNAs to the dorsal horn of the rat spinal cord. Neuropharmacology. 1993 Jan;32(1):37-41.</reference_text>
        <pubmed_id>7679210</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>L-Glutamic acid</name>
        <accession>HMDB00148</accession>
      </metabolite>
      <reference>
        <reference_text>Stein E, Cox JA, Seeburg PH, Verdoorn TA: Complex pharmacological properties of recombinant alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor subtypes. Mol Pharmacol. 1992 Nov;42(5):864-71.</reference_text>
        <pubmed_id>1279377</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>L-Glutamic acid</name>
        <accession>HMDB00148</accession>
      </metabolite>
      <reference>
        <reference_text>Li F, Owens N, Verdoorn TA: Functional effects of mutations in the putative agonist binding region of recombinant alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. Mol Pharmacol. 1995 Jan;47(1):148-54.</reference_text>
        <pubmed_id>7838123</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butabarbital</name>
        <accession>HMDB14382</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butabarbital</name>
        <accession>HMDB14382</accession>
      </metabolite>
      <reference>
        <reference_text>Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels.  Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303.</reference_text>
        <pubmed_id>10487207</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butalbital</name>
        <accession>HMDB14386</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butalbital</name>
        <accession>HMDB14386</accession>
      </metabolite>
      <reference>
        <reference_text>Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels.  Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303.</reference_text>
        <pubmed_id>10487207</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Talbutal</name>
        <accession>HMDB14451</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Talbutal</name>
        <accession>HMDB14451</accession>
      </metabolite>
      <reference>
        <reference_text>Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels.  Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303.</reference_text>
        <pubmed_id>10487207</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pentobarbital</name>
        <accession>HMDB14457</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pentobarbital</name>
        <accession>HMDB14457</accession>
      </metabolite>
      <reference>
        <reference_text>Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels.  Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303.</reference_text>
        <pubmed_id>10487207</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Secobarbital</name>
        <accession>HMDB14562</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Secobarbital</name>
        <accession>HMDB14562</accession>
      </metabolite>
      <reference>
        <reference_text>Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels.  Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303.</reference_text>
        <pubmed_id>10487207</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Metharbital</name>
        <accession>HMDB14606</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Metharbital</name>
        <accession>HMDB14606</accession>
      </metabolite>
      <reference>
        <reference_text>Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels.  Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303.</reference_text>
        <pubmed_id>10487207</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Thiopental</name>
        <accession>HMDB14737</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Thiopental</name>
        <accession>HMDB14737</accession>
      </metabolite>
      <reference>
        <reference_text>Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels.  Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303.</reference_text>
        <pubmed_id>10487207</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Primidone</name>
        <accession>HMDB14932</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Primidone</name>
        <accession>HMDB14932</accession>
      </metabolite>
      <reference>
        <reference_text>Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels.  Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303.</reference_text>
        <pubmed_id>10487207</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylphenobarbital</name>
        <accession>HMDB14987</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylphenobarbital</name>
        <accession>HMDB14987</accession>
      </metabolite>
      <reference>
        <reference_text>Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels.  Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303.</reference_text>
        <pubmed_id>10487207</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine barbiturate</name>
        <accession>HMDB15436</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine barbiturate</name>
        <accession>HMDB15436</accession>
      </metabolite>
      <reference>
        <reference_text>Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels.  Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303.</reference_text>
        <pubmed_id>10487207</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine barbiturate</name>
        <accession>HMDB15436</accession>
      </metabolite>
      <reference>
        <reference_text>Stobbs SH, Ohran AJ, Lassen MB, Allison DW, Brown JE, Steffensen SC: Ethanol suppression of ventral tegmental area GABA neuron electrical transmission involves N-methyl-D-aspartate receptors. J Pharmacol Exp Ther. 2004 Oct;311(1):282-9. Epub 2004 May 28.</reference_text>
        <pubmed_id>15169831</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amobarbital</name>
        <accession>HMDB15440</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amobarbital</name>
        <accession>HMDB15440</accession>
      </metabolite>
      <reference>
        <reference_text>Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels.  Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303.</reference_text>
        <pubmed_id>10487207</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aprobarbital</name>
        <accession>HMDB15441</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aprobarbital</name>
        <accession>HMDB15441</accession>
      </metabolite>
      <reference>
        <reference_text>Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels.  Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303.</reference_text>
        <pubmed_id>10487207</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butethal</name>
        <accession>HMDB15442</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butethal</name>
        <accession>HMDB15442</accession>
      </metabolite>
      <reference>
        <reference_text>Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels.  Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303.</reference_text>
        <pubmed_id>10487207</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Heptabarbital</name>
        <accession>HMDB15443</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Heptabarbital</name>
        <accession>HMDB15443</accession>
      </metabolite>
      <reference>
        <reference_text>Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels.  Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303.</reference_text>
        <pubmed_id>10487207</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3'-Hydroxyhexobarbital</name>
        <accession>HMDB13940</accession>
      </metabolite>
      <reference>
        <reference_text>Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action.  Annu Rev Pharmacol Toxicol. 2001;41:23-51.</reference_text>
        <pubmed_id>11264449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3'-Hydroxyhexobarbital</name>
        <accession>HMDB13940</accession>
      </metabolite>
      <reference>
        <reference_text>Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels.  Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303.</reference_text>
        <pubmed_id>10487207</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
